SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant buying momentum as community members discuss its potential for a short squeeze and long-term utility within the Solana DeFi ecosystem. Traders are actively debating entry points and price targets while highlighting the platform's role as a key decentralized exchange for Solana.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is currently a focal point for investors due to positive clinical data for its lead oncology programs, alongside ongoing institutional accumulation and anticipation of near-term catalyst readouts. The community is actively debating the company's valuation, pipeline depth in synthetic lethality, and the potential for a strategic M&A event given its highly proprietary platform.

Maulcoin

Maulcoin is trending as investors debate its long-term viability, with the community actively split between supporters pushing for growth around upcoming May 4th milestones and critics labeling the project a potential rug pull. Sentiment remains highly polarized, driven by ongoing internal tensions and aggressive cross-platform promotion efforts.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

Dave Inc. is trending as traders closely monitor its technical breakout potential and strong Q3 performance, with the community highlighting its high operating leverage and the disruptive potential of its AI-powered underwriting platform. Investors remain focused on the company's path to profitability and its strategic positioning in the neobanking sector, often drawing comparisons to other high-growth fintech peers.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently facing significant volatility following a convertible notes offering and insider share sales, leaving the community divided between long-term confidence in its gene-editing pipeline and frustration over the company's management and share performance. Traders are closely monitoring upcoming clinical data readouts and potential acquisition interest while debating whether the current price represents a generational buying opportunity or ongoing stagnation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to community-fueled speculation following a security disturbance at the White House Correspondents' Dinner, with many investors debating whether the event was a genuine threat or a staged distraction. Discussions are heavily polarized, with users analyzing security footage, questioning the timing relative to the administration's political challenges, and expressing frustration over the stock's volatility amidst this broader political theater.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is trending as investors closely monitor upcoming management updates and earnings, with community sentiment split between frustration over delayed Si-28 isotope shipment timelines and optimism regarding the company's long-term position in the strategic helium and nuclear fuel markets. Traders are particularly focused on potential catalysts like commercial production milestones and a possible spin-off, driving high engagement despite recent price volatility.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector is experiencing high investor interest driven by a wave of strategic M&A activity and positive clinical guideline updates, such as NCCN's expanded recommendations for oncology therapies. Investors are actively discussing the potential for structural squeezes in heavily shorted tickers and monitoring the interplay between biotech's clinical momentum and broader market macro volatility.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as shareholders react to an upbeat analyst initiation alongside growing anticipation for upcoming Phase 3 prostate cancer data at the American Urological Association meeting. The community is actively debating the stock's significant long-term potential compared to its current valuation, while traders closely monitor heavy short interest and strong volume as potential catalysts for further upward momentum.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is trending as community members speculate on its low circulating supply and potential for volatility, drawing comparisons to other small-cap assets. The conversation is dominated by users betting on a breakout while actively coordinating to drive interest and volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The combined company will be named Devon Energy and will be headquartered in Houston.</li><li>The merged company is expected to produce more than 1.6 million barrels of oil equivalent per day in Q3.</li><li>The transaction is expected to close in Q2.</li></ul>Devon Energy (DVN), on Monday, announced a definitive all-stock merger agreement with Coterra Energy (CTRA) to form a large-cap shale operator with an enterprise value of about $58 billion.The combined company will be named Devon Energy and will be headquartered in Houston.<a href="https://stocktwits.com/symbol/DVN">DVN shares</a> fell 2.9% in pre-market trading but gained marginally after the opening bell. <a href="https://stocktwits.com/symbol/CTRA">CTRA</a> stock was down 2.7%.<h2 class="st-heading-2">Transaction Details</h2>As part of the agreement, Coterra shareholders will receive 0.7 shares of Devon common stock for every Coterra share. After the transaction closes, Devon shareholders are expected to own approximately 54% of the combined company, while Coterra shareholders will hold the remaining 46%.Upon closing, which is expected in the second quarter (Q2) of fiscal 2026, the merged company plans to declare a quarterly dividend of $0.315 per share and establish a new share repurchase authorization of more than $5 billion post-close.The merged company is expected to produce more than 1.6 million barrels of oil equivalent per day in Q3, including more than 550,000 barrels of oil and 4.3 billion cubic feet of gas daily. The combined company expects to generate about $1 billion in annual pre-tax synergies by the end of 2027.“We've now built a diverse asset base of high-quality, long duration inventory to drive resilient value creation and returns for shareholders through cycles. Underpinned by our leading position in the best part of the Delaware Basin, and a deep set of complementary assets, we expect to capture annual pre-tax synergies of $1 billion. This will drive higher free cash flow and greater shareholder returns beyond what either company could achieve alone,” &nbsp;said Clay Gaspar, Devon’s President and CEO.&nbsp;Following the merger, the board will consist of 11 members, six directors from Devon and five from Coterra. Clay Gaspar will serve as President and CEO, while Tom Jorden will become a non-executive Chairman.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment for DVN and CRTA on Stocktwits was in the ‘bullish’ zone, accompanied by ‘high’ message volumes. &nbsp;One user was sceptical about DVN’s price action.<stembedurl>https://stocktwits.com/Never100trustthismarket/message/643669738</stembedurl>DVN shares have gained 10%, while CTRA stock has increased 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Oil pipelines, pumping rigs, and electrical transmission lines dot the landscape along California's "Petroleum Highway"

Devon Energy, Coterra To Form $58 Billion Shale Behemoth - DVN, CTRA Stocks Slip Pre-Market

Coterra shareholders will receive 0.7 shares of Devon common stock for every Coterra share.

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

CRZO
Carrizo Oil & Gas Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CRZO News

CRZOCarrizo Oil & Gas Inc.